➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Moodys
Boehringer Ingelheim
Medtronic
Dow

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Insulin aspart; insulin degludec - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin aspart; insulin degludec

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Colorado, DenverPhase 4
Mountain Diabetes and Endocrine CenterPhase 4
Merete Bechmann ChristensenPhase 4

See all insulin aspart; insulin degludec clinical trials

Recent Litigation for insulin aspart; insulin degludec

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
NOVO NORDISK INC. v. SANDOZ INC.2020-06-04
SMITH v. NOVO NORDISK INC.2016-08-08

See all insulin aspart; insulin degludec litigation

Company Disclosures: US Patents for insulin aspart; insulin degludec

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2016-06-20 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2021-01-05 DISCN company
Novo RYZODEG 70/30 insulin aspart; insulin degludec SOLUTION;SUBCUTANEOUS 203313 001 2016-03-07   Start Trial Novo Nordisk A/S (Bagsvaerd, DE) 2023-08-05 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin aspart; insulin degludec

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin aspart; insulin degludec

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2005 00018 Denmark   Start Trial PRODUCT NAME: INSULIN GLULISIN
0130014 00133 Estonia   Start Trial PRODUCT NAME: DEGLUDEKINSULIIN/ASPARTINSULIIN;REG NO/DATE: K(2013)368 (LOPLIK) 23.01.2013
17/022 Ireland   Start Trial PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
AstraZeneca
Dow
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.